Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
GLUE Stock Chart & Stats
$19.59
-$0.20(-2.99%)
At close: 4:00 PM EST
$19.59
-$0.20(-2.99%)
Day’s Range― - ―
52-Week Range$3.50 - $25.77
Previous CloseN/A
Volume283.19K
Average Volume (3M)2.06M
Market Cap
$1.49B
Enterprise Value$1.07B
Total Cash (Recent Filing)$391.26M
Total Debt (Recent Filing)$40.17M
Price to Earnings (P/E)64.1
Beta1.65
Next Earnings
Mar 12, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding76,242,760
10 Day Avg. Volume1,112,887
30 Day Avg. Volume2,056,072
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.30
Price to Sales (P/S)6.78
P/FCF Ratio13.50
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue5.89
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda54.67
Forecast
1Y Price Target
$33.80Price Target Upside72.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Competitive PositioningAnalyst observes MRT-8102's biomarker performance compares favorably to other NLRP3 and IL-6 targeted agents, which could strengthen strategic positioning versus competitors in the inflammatory cardiometabolic space.
Inflammation Biomarker EfficacyAnalyst notes MRT-8102 produced strong reductions in the inflammatory marker hsCRP and lowered IL-6 to levels associated with reduced cardiovascular risk, supporting early proof of concept for a cardio-metabolic indication.
Oncology Pipeline AdvancementAnalyst highlights evidence of activity for MRT-2359 combined with enzalutamide in metastatic prostate cancer with androgen receptor mutations and notes a plan to advance the combination into a Phase 2 study, enhancing pipeline value.
Bears Say
Clinical Data RobustnessAnalyst cautions that the small sample size and uncontrolled nature of the Phase 1/2 trial limit confidence in early efficacy signals and may necessitate larger controlled studies for validation.
Financing And Market PressureAnalyst warns that high short interest together with substantial cash burn raises financing risk and can increase share price volatility, potentially complicating capital strategy.
Safety ConcernAnalyst flags a serious liver enzyme elevation in one participant, with uncertainty about whether that participant received active drug, representing a safety issue that requires close monitoring.
Monte Rosa Therapeutics News
GLUE FAQ
What was Monte Rosa Therapeutics’s price range in the past 12 months?
Monte Rosa Therapeutics lowest stock price was $3.50 and its highest was $25.77 in the past 12 months.
What is Monte Rosa Therapeutics’s market cap?
Monte Rosa Therapeutics’s market cap is $1.49B.
When is Monte Rosa Therapeutics’s upcoming earnings report date?
Monte Rosa Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 27 days.
How were Monte Rosa Therapeutics’s earnings last quarter?
Monte Rosa Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.366 by $0.036.
Is Monte Rosa Therapeutics overvalued?
According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued.
Does Monte Rosa Therapeutics pay dividends?
Monte Rosa Therapeutics does not currently pay dividends.
What is Monte Rosa Therapeutics’s EPS estimate?
Monte Rosa Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Monte Rosa Therapeutics have?
Monte Rosa Therapeutics has 76,242,760 shares outstanding.
What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?
Monte Rosa Therapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.366. Following the earnings report the stock price went up 5.686%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics?
Currently, no hedge funds are holding shares in GLUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monte Rosa Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.80 (72.54% Upside)
$33.80 (72.54% Upside)
Blogger Sentiment
Bullish
GLUE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 848.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
190.65%
12-Months-Change
Fundamentals
Return on Equity
9.28%
Trailing 12-Months
Asset Growth
45.94%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
GLUE Stock 12 Month Forecast
Average Price Target
$33.80
▲(72.54% Upside)
Technical Analysis
CytomX Therapeutics
―
Fulcrum Therapeutics
―
Monopar Therapeutics Inc
―
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.95% Insiders
12.39% Mutual Funds
0.03% Other Institutional Investors
65.12% Public Companies and
Individual Investors